<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="18680" end="18686" sStart="18567" offset="113" sid="r11.strong.j.0979" wn="1" wnkey="strong%3:00:00::" annotator="vebatchelder" text="For example, vessels within tumors expressing predominantly the VEGF189 isoform, which has a strong heparin-binding affinity and thus is highly localized, are much less leaky than the vessels in tumors expressing the more diffusible VEGF165 and VEGF121 isoforms [ 45]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="1302" end="1308" sStart="null" offset="98" sid="r11.strong.j.0474" wn="2" wnkey="strong%5:00:00:intense:00" annotator="adelpriore" text="Two family members, acidic fibroblast growth factor (FGF-1) and FGF-2, have a strong affinity for heparin and have been studied for their effects on vascular cells, including endothelial cells and smooth muscle cells." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20181" end="20187" sStart="null" offset="0" sid="null" wn="3" wnkey="show%2:32:00::" annotator="carichter" text="Early studies involving the administration of VEGF-A &lt;b&gt;showed&lt;/b&gt; angiographic evidence of new vessel formation, but these vessels did not persist and they regressed within 3 months [ 40]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="3568" end="3574" sStart="null" offset="137" sid="r11.severe.j.0547" wn="1" wnkey="severe%5:00:00:intense:00" annotator="vebatchelder" text="In one early study using recombinant protein, a single intra-arterial injection of 500-1000 ?g VEGF165 into rabbits with severe experimental hind limb ischemia increased collateral vessels, as detected by angiography and histological analysis [ 6]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="2703" end="2709" sStart="null" offset="58" sid="r8.number.n.0936" wn="1" wnkey="number%1:07:00::" annotator="cgozo" text="The VEGF-A family of polypeptides consists of a number of biochemically distinct isoforms (three isoforms in the mouse and up to five in humans) that are generated through alternative mRNA splicing of a single gene [ 4, 5]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="23028" end="23034" sStart="null" offset="0" sid="r9.normal.j.0561" wn="3" wnkey="normal%3:00:03::" annotator="veweser" text="normal vascular development has been shown to require the presence of the CD45 +/c-Kit +/CD34 +hematopoietic stem cells [ 58], which are similar and may be related to adult CEP cells." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20747" end="20753" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="It has been speculated that VEGF-A alone may not be sufficient to form stable, &lt;b&gt;mature&lt;/b&gt; vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells [ 48]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20747" end="20753" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="It has been speculated that VEGF-A alone may not be sufficient to form stable, &lt;b&gt;mature&lt;/b&gt; vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells [ 48]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="21427" end="21433" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-? as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and &lt;b&gt;mature&lt;/b&gt; vessels (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20747" end="20753" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="It has been speculated that VEGF-A alone may not be sufficient to form stable, &lt;b&gt;mature&lt;/b&gt; vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells [ 48]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="19768" end="19774" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Vessels formed in response to artificial angiogenic stimuli are prone to regression unless they are remodeled into &lt;b&gt;mature&lt;/b&gt;, stable vessels [ 46]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="21427" end="21433" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-? as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and &lt;b&gt;mature&lt;/b&gt; vessels (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20747" end="20753" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="It has been speculated that VEGF-A alone may not be sufficient to form stable, &lt;b&gt;mature&lt;/b&gt; vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells [ 48]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="21427" end="21433" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-? as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and &lt;b&gt;mature&lt;/b&gt; vessels (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="20747" end="20753" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="It has been speculated that VEGF-A alone may not be sufficient to form stable, &lt;b&gt;mature&lt;/b&gt; vessels that are characterized by the recruitment of the perivascular mural cells, such as pericytes or smooth muscle cells [ 48]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="19768" end="19774" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Vessels formed in response to artificial angiogenic stimuli are prone to regression unless they are remodeled into &lt;b&gt;mature&lt;/b&gt;, stable vessels [ 46]." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="21427" end="21433" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-? as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and &lt;b&gt;mature&lt;/b&gt; vessels (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="5172" end="5180" sStart="null" offset="129" sid="r11.function.n.0239" wn="2" wnkey="function%1:07:00::" annotator="anfahmy" text="A single bolus injection was also found to produce significant improvements in myocardial blood flow and function [ 9]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="14430" end="14434" sStart="null" offset="12" sid="r9.fold.v.0725" wn="2147483645" wnkey="null" annotator="veweser" text="A nearly 10-fold range of response to the fixed dosage of FGF-2 was observed among different inbred strains of mice, suggesting that genetic variability may indeed play a significant role in determining the magnitude of angiogenic response to FGF-2." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="1054" end="1060" sStart="null" offset="35" sid="r8.family.n.0271" wn="3" wnkey="family%1:14:04::" annotator="brubin" text="The fibroblast growth factor (FGF) family consists of an ever-increasing number of peptide growth factors with diverse cellular targets and biological effects [ 1]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="24649" end="24653" sStart="null" offset="48" sid="r7.1.easy.j.0317" wn="1" wnkey="easy%3:00:01::" annotator="veweser" text="Finally, since the use of CEP cells would allow easy ex vivo gene transfer, combining growth factor-induced therapeutic angiogenesis with gene therapy delivered via CEP should also be a promising approach." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="24490" end="24499" sStart="null" offset="87" sid="r8.1.different.j.0300" wn="1" wnkey="different%3:00:00::" annotator="cgozo" text="The possibility of using CEP cells, both alone and in combination with different angiogenic growth factors, represents a promising means of obtaining stable vessels." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="18013" end="18022" sStart="null" offset="57" sid="r8.1.different.j.0971" wn="1" wnkey="different%3:00:00::" annotator="brubin" text="It is therefore important to determine whether different VEGF-A isoforms give rise to different quality or quantity of vessels." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/cvm-2-6-278.anc" start="15580" end="15584" sStart="null" offset="0" sid="null" wn="4" wnkey="date%1:28:02::" annotator="cgozo" text="In contrast, there has been no evidence of disease progression, to &lt;b&gt;date&lt;/b&gt;, in 42 patients treated with intra-arterial gene transfer of naked VEGF-A cDNA." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="16064" end="16072" sStart="null" offset="221" sid="r10.control.n.0215" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="Although these observations suggest that human sensitivity to VEGF-A may be lower than in animal models, it will be necessary to study a larger cohort of patients, with appropriate controls, over a longer time period to confirm this [ 36]." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="10411" end="10418" sStart="null" offset="124" sid="r10.control.n.0134" wn="2147483645" wnkey="null" annotator="anfahmy" text="Delivery of intracellular modulators for therapeutic angiogenesis, including transcription factors that control angiogenesis such as hypoxia inducible factor-1 alpha (HIF-1?), is only possible through gene therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="21376" end="21388" sStart="null" offset="242" sid="r11.combination.n.0728" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Various growth factors such as angiopoietin (ang)-1, platelet-derived growth factor, transforming growth factor-? as well as VEGF-A are also involved in arteriogenesis, and it may therefore be necessary to use combinations of these factors to obtain stable and mature vessels (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/cvm-2-6-278.anc" start="24473" end="24484" sStart="null" offset="70" sid="r11.combination.n.0647" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="The possibility of using CEP cells, both alone and in combination with different angiogenic growth factors, represents a promising means of obtaining stable vessels." />
  </sentences>
</list>